Department of Internal Medicine IV, Oncology/Hematology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
J Clin Invest. 2021 Jan 4;131(1). doi: 10.1172/JCI142966.
A considerable fraction of B cells recognize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with germline-encoded elements of their B cell receptor, resulting in the production of neutralizing and nonneutralizing antibodies. We found that antibody sequences from different discovery cohorts shared biochemical properties and could be retrieved across validation cohorts, confirming the stereotyped character of this naive response in coronavirus disease 2019 (COVID-19). While neutralizing antibody sequences were found independently of disease severity, in line with serological data, individual nonneutralizing antibody sequences were associated with fatal clinical courses, suggesting detrimental effects of these antibodies. We mined 200 immune repertoires from healthy individuals and 500 repertoires from patients with blood or solid cancers - all acquired prior to the pandemic - for SARS-CoV-2 antibody sequences. While the largely unmutated B cell rearrangements occurred in a substantial fraction of immune repertoires from young and healthy individuals, these sequences were less likely to be found in individuals over 60 years of age and in those with cancer. This reflects B cell repertoire restriction in aging and cancer, and may to a certain extent explain the different clinical courses of COVID-19 observed in these risk groups. Future studies will have to address if this stereotyped B cell response to SARS-CoV-2 emerging from unmutated antibody rearrangements will create long-lived memory.
相当一部分 B 细胞通过其 B 细胞受体的胚系编码元件识别严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2),从而产生中和性和非中和性抗体。我们发现,来自不同发现队列的抗体序列具有生化特性,并可在验证队列中检索,这证实了 2019 年冠状病毒病 (COVID-19) 中这种幼稚反应的定型特征。虽然中和抗体序列的发现与疾病严重程度无关,与血清学数据一致,但个体非中和抗体序列与致命临床病程相关,表明这些抗体存在有害影响。我们从健康个体中挖掘了 200 个免疫库,从患有血液或实体癌的患者中挖掘了 500 个免疫库,以寻找 SARS-CoV-2 抗体序列。虽然在年轻和健康个体的大量未突变 B 细胞重排中发生了这种情况,但在 60 岁以上的个体和癌症患者中,这些序列不太可能被发现。这反映了衰老和癌症中 B 细胞库的限制,并且在一定程度上可以解释在这些风险群体中观察到的 COVID-19 不同临床病程。未来的研究将不得不解决从未突变的抗体重排中出现的针对 SARS-CoV-2 的这种定型 B 细胞反应是否会产生长期记忆。